Work Reintegration Following Low-Grade Glioma Treatment: Evaluating Return Rates and Identifying Patient Challenges - Top-Institutions - MDSpire

Work Reintegration Following Low-Grade Glioma Treatment: Evaluating Return Rates and Identifying Patient Challenges

  • By

  • Jasmine C. Kennedy

  • Stephen J. Price

  • Tom Manly

  • Emma Woodberry

  • Mary Burton

  • April 21, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Cognitive Rehabilitation
    • Brain Tumor Research

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuro-oncology
    • Rehabilitation Medicine
    • Cancer Survivorship

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-oncology
    • Neuropsychology
    • Cancer Rehabilitation

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neuro-oncology
    • Neuropsychology
    • Rehabilitation Medicine

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neuro-oncology
    • Neuropsychology
    • Cancer Survivorship

Original Source(s)

Work Reintegration Following Low-Grade Glioma Treatment: Evaluating Return Rates and Identifying Patient Challenges

  • by Jasmine C. Kennedy, Stephen J. Price, Tom Manly, Emma Woodberry, Mary Burton

  • April 21, 2026

Related Content

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.

Human neural organoid modeling of diffuse midline glioma captures the complexity of patient tumors